Photos show two suspects in the shooting of a teen boy on a SEPTA bus By Emily Rose Grassi and David Chang • Published October 8, 2024 • Updated on October 10, 2024 at 10:17 pm ...

Overall, 25.9% of patients on 80-mg resmetirom and 29.9% of patients on 100-mg resmetirom experienced NASH resolution with no worsening of fibrosis compared with just 9.7% on the placebo.

In the so-called MAESTRO-NASH study, NASH resolution with no worsening of fibrosis was achieved in 25.9% of patients who received the investigational drug at the 80-mg dose and 29.9% of those ...

We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were ...

A therapeutic being tested for nonalcoholic steatohepatitis (NASH) and liver fibrosis showed statistically significant improvement versus placebo on two primary endpoints in a one-year, Phase 2b trial ...

Findings showed that 26% and 30% of patients treated with resmetirom 80mg and 100mg, respectively, achieved NASH resolution with at least a 2-point reduction in NAS and no worsening of fibrosis ...

NASH-related Fibrosis Treatment The researchers found that the drug, called Pegozafermin, mimicked fibroblast growth factor 21 (FGF21) — a liver-secreted peptide hormone that is naturally ...

Resmetirom at 80 mg and 100 mg helped 26% and 30% of patients, respectively, achieve NASH resolution with no worsening of fibrosis, versus 10% for placebo.

The multicenter, double-blind HARMONY trial randomized 128 patients with NASH and fibrosis stages 2-3 to a once-weekly dose of 50 mg or 28 mg efruxifermin or placebo for 24 weeks.

After 24 weeks, around 40% of recipients of efruxifermin experienced a one stage or more improvement in fibrosis without worsening of NASH, compared to 20% of their counterparts in the control arm ...

The paper, published in leading journal Gut, identified two protein biomarkers, PLIN2 and RAB14, that were used as part of an algorithm to identify people with NASH and/or liver fibrosis.